List of Excipients in API ERTUGLIFLOZIN
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing ERTUGLIFLOZIN
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | CELLULOSE, MICROCRYSTALLINE | |
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | FERRIC OXIDE RED | |
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | HYPROMELLOSE 2910 | |
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | LACTOSE MONOHYDRATE | |
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | MAGNESIUM STEARATE | |
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | POLYETHYLENE GLYCOL 3350 | |
| Merck Sharp & Dohme LLC | STEGLATRO | ertugliflozin | 0006-5363 | SODIUM STARCH GLYCOLATE TYPE A POTATO | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for ERTUGLIFLOZIN
Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE
ERTUGLIFLOZIN drug variants containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Excipient focus: CARNAUBA WAX
ERTUGLIFLOZIN drug variants containing CARNAUBA WAX
ERTUGLIFLOZIN drug variants not containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
ERTUGLIFLOZIN drug variants containing CELLULOSE, MICROCRYSTALLINE
ERTUGLIFLOZIN drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
ERTUGLIFLOZIN drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing CROSCARMELLOSE SODIUM
Excipient focus: CROSPOVIDONE
ERTUGLIFLOZIN drug variants containing CROSPOVIDONE
ERTUGLIFLOZIN drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
ERTUGLIFLOZIN drug variants containing FERRIC OXIDE RED
ERTUGLIFLOZIN drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
ERTUGLIFLOZIN drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing FERRIC OXIDE YELLOW
Excipient focus: FERROSOFERRIC OXIDE
ERTUGLIFLOZIN drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing FERROSOFERRIC OXIDE
Excipient focus: HYDROXYPROPYL CELLULOSE
ERTUGLIFLOZIN drug variants containing HYDROXYPROPYL CELLULOSE
ERTUGLIFLOZIN drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
ERTUGLIFLOZIN drug variants containing HYPROMELLOSE
ERTUGLIFLOZIN drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
ERTUGLIFLOZIN drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing HYPROMELLOSE 2910
Excipient focus: LACTOSE MONOHYDRATE
ERTUGLIFLOZIN drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing LACTOSE MONOHYDRATE
Excipient focus: MAGNESIUM STEARATE
ERTUGLIFLOZIN drug variants containing MAGNESIUM STEARATE
ERTUGLIFLOZIN drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
ERTUGLIFLOZIN drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing POLYETHYLENE GLYCOL 3350
Excipient focus: POVIDONE
ERTUGLIFLOZIN drug variants containing POVIDONE
ERTUGLIFLOZIN drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYL GALLATE
ERTUGLIFLOZIN drug variants containing PROPYL GALLATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing PROPYL GALLATE
Excipient focus: SODIUM LAURYL SULFATE
ERTUGLIFLOZIN drug variants containing SODIUM LAURYL SULFATE
ERTUGLIFLOZIN drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
ERTUGLIFLOZIN drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
Excipient focus: SODIUM STEARYL FUMARATE
ERTUGLIFLOZIN drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin and sitagliptin | 0006-5367 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing SODIUM STEARYL FUMARATE
Excipient focus: TITANIUM DIOXIDE
ERTUGLIFLOZIN drug variants containing TITANIUM DIOXIDE
ERTUGLIFLOZIN drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
ERTUGLIFLOZIN drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | ertugliflozin | 0006-5363 |
| A-S Medication Solutions | ertugliflozin | 50090-6182 |
| A-S Medication Solutions | ertugliflozin | 50090-6183 |
| >Company | >Ingredient | >NDC |
ERTUGLIFLOZIN drug variants not containing TRIACETIN
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
